Javascript must be enabled to continue!
Clinical psychiatric pharmacist involvement in an outpatient buprenorphine program
View through CrossRef
Background: Approximately nineteen million individuals in the United States are diagnosed with a substance use disorder (SUD), including many veterans enrolled in the Veterans Health Administration (VHA). The prevalence of SUD within the veteran population has been steadily increasing, resulting in increased utilization of substance abuse services, such as buprenorphine programs for opioid dependence. As this population grows, there is an increased need for multidisciplinary services. Clinical psychiatric pharmacists do not have prescriptive authority for buprenorphine, but can play a vital role in outpatient buprenorphine programs.
Description of Innovative Service: The clinical psychiatric pharmacist is involved in many aspects of the outpatient buprenorphine program. There are over 100 patients enrolled in the buprenorphine program at the White River Junction Veterans Affairs Medical Center (WRJVAMC). The clinical pharmacist devotes approximately ten hours per week to the program, which includes dispensing the medication, monitoring lab values, patient counseling and random medication counts. A spreadsheet is maintained and updated weekly to monitor doses, refill dates and urine toxicology results. The clinical pharmacist is also involved in the dispensing process in the outpatient pharmacy; this allows for open communication between the clinical pharmacist and patient.
Impact on Patient Care: The clinical psychiatric pharmacist has been involved in the outpatient buprenorphine program at the WRJVAMC for approximately two years. Prior to this, the program included less than 100 patients, pharmacy wait times were over sixty minutes and early refills were frequent. Since clinical pharmacy involvement, the pharmacy wait time is approximately 30 minutes or less and early refills are infrequent. Patient satisfaction has also significantly improved. The clinical pharmacist has helped open the lines of communication between the patient, the pharmacy and the prescriber.
Conclusion: Substance use disorder programs, such as buprenorphine programs, can benefit from clinical pharmacy involvement. Even with limited prescriptive authority, clinical psychiatric pharmacists can play an important and active role in outpatient buprenorphine programs.
Title: Clinical psychiatric pharmacist involvement in an outpatient buprenorphine program
Description:
Background: Approximately nineteen million individuals in the United States are diagnosed with a substance use disorder (SUD), including many veterans enrolled in the Veterans Health Administration (VHA).
The prevalence of SUD within the veteran population has been steadily increasing, resulting in increased utilization of substance abuse services, such as buprenorphine programs for opioid dependence.
As this population grows, there is an increased need for multidisciplinary services.
Clinical psychiatric pharmacists do not have prescriptive authority for buprenorphine, but can play a vital role in outpatient buprenorphine programs.
Description of Innovative Service: The clinical psychiatric pharmacist is involved in many aspects of the outpatient buprenorphine program.
There are over 100 patients enrolled in the buprenorphine program at the White River Junction Veterans Affairs Medical Center (WRJVAMC).
The clinical pharmacist devotes approximately ten hours per week to the program, which includes dispensing the medication, monitoring lab values, patient counseling and random medication counts.
A spreadsheet is maintained and updated weekly to monitor doses, refill dates and urine toxicology results.
The clinical pharmacist is also involved in the dispensing process in the outpatient pharmacy; this allows for open communication between the clinical pharmacist and patient.
Impact on Patient Care: The clinical psychiatric pharmacist has been involved in the outpatient buprenorphine program at the WRJVAMC for approximately two years.
Prior to this, the program included less than 100 patients, pharmacy wait times were over sixty minutes and early refills were frequent.
Since clinical pharmacy involvement, the pharmacy wait time is approximately 30 minutes or less and early refills are infrequent.
Patient satisfaction has also significantly improved.
The clinical pharmacist has helped open the lines of communication between the patient, the pharmacy and the prescriber.
Conclusion: Substance use disorder programs, such as buprenorphine programs, can benefit from clinical pharmacy involvement.
Even with limited prescriptive authority, clinical psychiatric pharmacists can play an important and active role in outpatient buprenorphine programs.
Related Results
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract
Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...
A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use
A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use
Introduction:
An increasing number of individuals are taking buprenorphine for management of opioid use disorder (OUD). Pain control can be challenging when these patie...
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
Background: Current guidelines for pregnant women with substance use disorder advise prenatal maintenance of opioid agonist therapy with either buprenorphine or methadone. Despite ...
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
ImportanceBuprenorphine treatment of opioid use disorder (OUD) is safe and effective, but opioid withdrawal during treatment initiation is associated with poor retention in care. A...
Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified
Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified
AbstractBuprenorphine is dispensed primarily in community pharmacies in Victoria, with buprenorphine prescribing expanding nationally. The aim of this paper was to examine issues t...
Trends in Access to Medications for Opioid Use Disorder
Trends in Access to Medications for Opioid Use Disorder
ImportanceMedicaid, the largest payer for medications for opioid use disorder (MOUD), disenrolled more than 19.1 million individuals by March 2024 after the continuous coverage req...
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
Objective: This study compared opioid utilization and clinical outcomes in surgical patients receiving maintenance buprenorphine therapy who discontinued versus those who continued...
0487 Chronic Buprenorphine-Induced Central Sleep Apnea and Desaturation
0487 Chronic Buprenorphine-Induced Central Sleep Apnea and Desaturation
Abstract
Introduction
Individuals on opioids are found dead in bed and respiratory depression is a potential cause. In co...

